Long‐Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients
暂无分享,去创建一个
W. Haefeli | J. Burhenne | E. Ngaimisi | P. Sasi | S. Mugusi | N. Ueda | E. Aklillu | O. Minzi | M. Janabi | F. Mugusi | K. Riedel | A. Suda | O. Minzi | Jürgen Burhenne | Walter E. Haefeli | Nobuhisa Ueda
[1] Zeruesenay Desta,et al. Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation , 2010, Drug Metabolism and Disposition.
[2] V. Preedy,et al. Prospective Cohort Study , 2010 .
[3] L. Milani,et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.
[4] D. Grasela,et al. Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine , 2009, Antimicrobial Agents and Chemotherapy.
[5] M. J. García,et al. Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients , 2009, Antimicrobial Agents and Chemotherapy.
[6] S. Staszewski,et al. Factors associated with viral rebound among highly treatment‐experienced HIV‐positive patients who have achieved viral suppression , 2009, HIV medicine.
[7] W. Haefeli,et al. Induction of multiple drug transporters by efavirenz. , 2009, Journal of pharmacological sciences.
[8] Jingdong Xie,et al. Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy Subjects , 2008, Journal of clinical pharmacology.
[9] Prosper Chonzi,et al. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.
[10] W. Haefeli,et al. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. , 2007, Rapid communications in mass spectrometry : RCM.
[11] Hongbing Wang,et al. Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.
[12] K. Tashima,et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] M. Hirsch,et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.
[14] S. Khoo,et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.
[15] T. Puthanakit,et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] A. Y. Lu,et al. METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION? , 2005, Drug Metabolism and Disposition.
[17] F. Maggiolo,et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[19] A. Sönnerborg,et al. Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.
[20] D. Greenblatt,et al. Differential Modulation of P-Glycoprotein Expression and Activity by Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors in Cell Culture , 2002, Pharmaceutical Research.
[21] J. Schubert,et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. , 2003, European journal of medical research.
[22] A. Mocroft,et al. Virological rebound after suppression on highly active antiretroviral therapy , 2003, AIDS.
[23] S. Khoo,et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. , 2003, Journal of acquired immune deficiency syndromes.
[24] C. Bellodi,et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients , 2003, AIDS.
[25] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[26] Jacques Fellay,et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.
[27] J. Barrett,et al. Population pharmacokinetic meta-analysis with efavirenz. , 2002, International journal of clinical pharmacology and therapeutics.
[28] H. Klinker,et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. , 2002, European journal of medical research.
[29] P. Watkins,et al. Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans , 2002, Clinical pharmacology and therapeutics.
[30] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[31] V. Soriano,et al. Higher efavirenz plasma levels correlate with development of insomnia. , 2001, Journal of acquired immune deficiency syndromes.
[32] Brendan Larder,et al. Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy , 2001, Journal of Virology.
[33] A. Telenti,et al. Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .
[34] Patrick F. Smith,et al. Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors , 2001, Clinical pharmacokinetics.
[35] A. Mocroft,et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.
[36] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[37] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[38] A. Shepherd,et al. Reduced induction of drug metabolism in the elderly. , 1978, Age and ageing.